Millions of Americans undergo annual cholesterol screening that may not be catching their actual cardiovascular risk. New research from Northwestern Medicine suggests doctors have been using the wrong metric to decide who needs aggressive treatment for cholesterol, and switching tests could prevent a significant number of heart attacks and strokes.
The study, published in JAMA, compared three cholesterol-testing strategies and found that measuring apolipoprotein B (apoB) outperformed the standard LDL cholesterol test that dominates routine practice today. When used to guide treatment decisions, apoB identified more people at genuine risk and did so in a cost-effective manner, according to the analysis.
"We found that apoB testing to intensify cholesterol-lowering medication would prevent more heart attacks and strokes than current practice, and that these health benefits were achieved at a cost that represents good value for U.S. healthcare payers," said Ciaran Kohli-Lynch, assistant professor of preventive medicine at Northwestern University Feinberg School of Medicine and lead author of the study.
The distinction matters because heart disease remains the leading cause of death in the United States. Over time, cholesterol-carrying particles accumulate inside artery walls, building up into plaques that restrict blood flow and trigger cardiovascular events. Current treatment decisions rely on LDL and non-HDL cholesterol levels, but these measurements don't fully capture who is truly at risk.
Why particle count beats cholesterol levels
ApoB works differently. Instead of measuring cholesterol concentration, it counts the actual number of harmful particles in the bloodstream. This distinction is crucial because two patients with identical LDL levels may carry vastly different numbers of cholesterol particles, meaning their actual risk profiles diverge significantly.
"Research strongly shows that apolipoprotein B is better at identifying who is at risk, because it counts the total number of harmful particles in the blood," Kohli-Lynch explained.
The test has gained momentum in clinical research, but adoption remains sluggish. One barrier is practical: apoB testing typically requires an additional blood draw beyond the standard cholesterol panel, adding cost and patient inconvenience. Doctors accustomed to the familiar LDL framework have had little incentive to change.
Kohli-Lynch's team used computer modeling to test whether the extra expense justified the switch. They simulated treatment strategies for 250,000 U.S. adults eligible for statin therapy but without existing cardiovascular disease. The model compared how well each approach predicted who would benefit from intensified cholesterol-lowering therapy.
This is the first comprehensive analysis to demonstrate that apoB-guided treatment is both more effective and cost-effective than current practice, according to the Northwestern researchers.
The findings arrive as healthcare systems grapple with spiraling cardiovascular disease costs and preventable heart attacks. If apoB testing were adopted widely, it could shift which patients receive aggressive statin therapy and at what dosage, potentially redirecting resources toward those with the highest particle burden rather than those whose cholesterol numbers appear high on a conventional test.
The barrier now is institutional inertia and the fact that LDL remains the standard metric embedded in treatment guidelines, clinical workflows, and patient education. Widespread adoption would require changing established practices across millions of annual checkups.
Author Jessica Williams: "If this study holds up, ignoring apoB becomes a public health oversight that's harder to excuse."
Comments